Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jinju
Clinical trial register · South Korea

Clinical Trials in Jinju, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca14 Novartis Pharmaceuticals4 Taiho Oncology, Inc.4 BioNTech SE4 AbbVie3
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Jinju

58 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA
NCT07570394Chronic Obstructive Pulmonary Disease (COPD), Asthma
AstraZeneca
Observational
600
Chuncheon, Daegu, Goyang-si, Gwangmyeong, Jinju, Seongnam-si, Seoul, Wŏnju
2026-09-17
Not yet open
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
NCT07684742Acute Coronary Syndromes, STEMI, NSTEMI, Unstable Angina
Gyeongsang National University Hospital
Phase 4
1,900
Jinju
2026-07-01
Active, closed
Taiho Oncology, Inc.
Phase 3
360
Daegu, Seongnam-si, Suwon, Cheongju-si, Goyang-si, Pusan, Yangsan, Jinju
2025-12-22
Recruiting
Daiichi Sankyo
Phase 3
686
Cheongju-si, Goyang-si, Jinju, Seongnam, Seoul, Suwon
2025-10-24
Recruiting
Eli Lilly and Company
Phase 3
4,500
Ansan-si, Bucheon-si, Busan, Daegu, Dongjak-gu, Guri-si, Incheon, Jinju
2025-10-15
Recruiting
Samsung Medical Center
Not applicable
3,500
Bucheon-si, Daegu, Gwangju, Gwangmyeong, Ilsan, Incheon, Jeonju, Jinju
2025-10-02
Recruiting
BeOne Medicines
Phase 3
500
Seogu, Seongnam-si, Jinju, SeochoGu, SeodaemunGu, Seoul
2025-09-04
Recruiting
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT07002164Myocardial Infarction (MI), Heart Failure
Chonnam National University Hospital
Not applicable
780
Changwon, Daegu, Daejeon, Gwangju, Jeonju, Jinju, Pusan, Seongnam
2025-07-15
Recruiting
Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
NCT07405931Early Gastric Cancer, Advanced Gastric Cancer, Early Lung Cancer, Advanced Lung Cancer
Ulsan University Hospital
Not applicable
414
Busan, Goyang, Incheon, Jinju, Ulsan
2025-07-09
Recruiting
AstraZeneca
Phase 3
830
Jinju, Seoul
2025-04-10
Recruiting
Novartis Pharmaceuticals
Observational
70
Jinju, Busan, Gwangju
2025-04-02
Recruiting
BioNTech SE
Phase 2
60
Jinju, Cheongju-si, Incheon, Seoul
2025-03-03
Recruiting
BioNTech SE
Phase 3
621
Seoul, Goyang-si, Suwon, Jinju, Incheon, Cheongju-si
2025-02-03
Recruiting
BioNTech SE
Phase 2/3
1,580
Cheongju-si, Daejeon, Goyang-si, Incheon, Jinju, Seongnam-si, Seoul, Suwon
2025-01-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Wŏnju, Gwangju, Ansan-si, Jinju, Pusan, Deagu, Seoul
2024-12-02
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Cheongju-si, Jinju, Seoul
2024-11-22
Recruiting
AstraZeneca
Phase 3
744
Busan, Chungcheongbuk-do, Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon
2024-10-04
Recruiting
Bayer
Phase 3
555
Suwon, Jinju, Yangsan, Hwasun-gun, Chungcheongbuk-do, Jongno -Gu, Seoul
2024-08-28
Active, closed
BioNTech SE
Phase 2
110
Cheongju-si, Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon
2024-08-05
Recruiting
OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts
NCT06227754ST Elevation Myocardial Infarction, Myocardial Infarction
Chonnam National University Hospital
Not applicable
1,500
Daegu, Gwangju, Iksan, Incheon, Jeju City, Jeonju, Jinju, Seoul
2024-03-25
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Cheongju Chungbuk, Goyang-si Gyeonggi-do, Incheon, Jinju, Seongnam-si, Gyeonggi-do, Seoul
2024-02-20
Active, closed
Samsung Bioepis Co., Ltd.
Phase 1
163
Ansan, Busan, Daegu, Hwasun, Incheon, Jinju, Seongnam, Seoul
2024-01-16
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 3
200
Seongnam-si, Jinju, Hwasun, Busan, Daegu, Incheon, Seoul
2023-12-20
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Seongnam-si, Suwon, Jinju, Incheon, Seoul
2023-12-18
Recruiting
AbbVie
Phase 1
325
Busan, Jinju, Cheongju-si, Seoul
2023-11-09
Active, closed
AstraZeneca
Phase 3
895
Cheongju-si, Incheon, Jinju, Seoul, Suwon
2023-10-24
Recruiting
Acrotech Biopharma Inc.
Phase 3
504
Busan, Ulsan, Suwon, Jinju, Jeonju, Daegu, Sinchon-dong, Songpa-dong
2023-10-04
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Goyang-si, Suwon, Jinju, Incheon, Hwasun-gun, Seoul, Soeul
2023-07-31
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Busan, Daegu, Jinju, Seongnam, Seoul
2023-07-05
Active, closed
Amgen
Phase 3
509
Cheongju Chungbuk, Goyang-si Gyeonggi-do, Incheon, Jinju, Seongnam-si, Gyeonggi-do, Seoul, Ulsan
2023-05-31
Recruiting
Seoul National University Bundang Hospital
Observational
1,240
Daegu, Gyeonggi-do, Hwasun, Ilsan, Jinju, Seongnam-si, Seoul, Yangsan
2023-04-01
Recruiting
Abion Inc
Phase 2
178
Goyang-si, Suwon, Dongjak, Seoul, Sinchon-dong, Cheongju-si, Incheon, Jinju
2023-01-17
Active, closed
AstraZeneca
Phase 3
1,350
Busan, Cheongju-si, Jinju, Seoul, Suwon
2022-12-29
Recruiting
Yuhan Corporation
Phase 1/2
147
Seongnam-si, Suwon, Jinju, Cheongju-si, Incheon, Seoul, Ulsan
2022-08-26
Active, closed
AstraZeneca
Phase 3
341
Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon
2022-08-03
Active, closed
Drug-Coated Balloon in Patients With High Bleeding Risk
NCT05221931Coronary Artery Disease
Samsung Medical Center
Not applicable
1,359
Ansan, Cheongju-si, Daegu, Gangneung, Gwangju, Gwangmyeong, Incheon, Jinju
2022-07-29
Active, closed
Novartis Pharmaceuticals
Observational
670
Daegu, Kangwon Do, Wŏnju, Goyang-si, Guri-si, Jinju, Jeonju, Iksan Si
2022-05-09
Active, closed
Multicenter Registry of Coronary Flow-Derived Indexes for Coronary Microvascular Disease (Multicenter FLOW-CMD Registry)
NCT05369182Coronary Microvascular Disease, Coronary Artery Disease, Ischemic Heart Disease
Samsung Medical Center
Observational
1,003
Gwangju, Jinju, Seongnam, Seoul
2022-04-22
Recruiting
AbbVie
Phase 3
768
Goyang-si, Seongnam, Suwon, Jinju, Yangsan, Cheongju-si, Seoul
2022-03-25
Active, closed
BeOne Medicines
Phase 3
799
BusanjinGu, Seogu, Seongnam-si, BukGu, Jinju, HwasunGun, GangnamGu, SeochoGu
2022-03-10
Active, closed
Daiichi Sankyo
Phase 3
740
Seongnam-si, Jinju, Cheongju-si, Daegu, Goyang-si, Seoul, Songpa-gu
2022-03-04
Active, closed
AstraZeneca
Phase 3
390
Daegu, Jinju, Seoul, Suwon
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon
2022-02-18
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Daegu, Wŏnju, Bundang Gu, Jinju, Yangsan, Incheon, Seoul, Cheongju-si
2021-11-23
Active, closed
AbbVie
Phase 1
520
Busan, Seongnam, Jinju, Cheongju-si, Seoul
2021-10-13
Active, closed
Incyte Corporation
Phase 3
899
Busan, Daegu, Goyang-si, Incheon, Jeonju, Jinju, Seoul, Yangsan
2021-05-11
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Jinju, Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Ulsan
2021-04-09
Recruiting
AstraZeneca
Phase 1
304
Cheongju-si, Goyang-si, Jinju, Seoul
2021-03-09
Active, closed
AstraZeneca
Phase 2
31
Cheongju-si, Jinju, Seoul
2021-02-23
Active, closed
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04736173Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
DrugsDomvanalimab·Zimberelimab·Pemetrexed·Paclitaxel
Arcus Biosciences, Inc.
Phase 2
169
Daegu, Incheon, Jinju, Seoul, Suwon
2021-02-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Goyang-si, Seongnam-si, Suwon, Jinju, Cheongju-si, Daegu, Seoul
2020-07-06
Active, closed
Eli Lilly and Company
Phase 3
261
Goyang-si, Seongnam-si, Incheon, Seoul, Jinju, Dongjak-gu, Daejeon
2020-02-17
Active, closed
Timing of FFR-guided PCI for Non-IRA in STEMI and MVD (OPTION-STEMI)
NCT04626882Myocardial Infarction, Acute, Multi-Vessel Coronary Artery Stenosis
Chonnam National University Hospital
Not applicable
994
Bucheon-si, Changwon, Daegu, Gangneung, Gwangju, Jeonju, Jinju, Seoul
2019-12-30
Active, closed
AstraZeneca
Phase 3
730
Changwon-si, Cheongju-si, Daegu, Goyang-si, Jinju, Seongnam-si, Seoul, Suwon
2018-09-27
Active, closed
AstraZeneca
Phase 3
987
Changwon, Cheongju-si, Daegu, Incheon, Jinju, Seongnam-si, Seoul
2017-03-27
Active, closed
AstraZeneca
Phase 3
669
Changwon-si, Cheongju-si, Daegu, Incheon, Jinju, Seoul, Suwon
2017-01-02
Active, closed
AstraZeneca
Phase 3
1,118
Busan, Changwon-si, Cheongju-si, Daegu, Daejeon, Goyang-si, Incheon, Jinju
2015-07-21
Active, closed
Eli Lilly and Company
Phase 3
545
Cheongju-si, Seongnam, Suwon, Jinju, Seoul, Ulsan
2015-05-06
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/jinju

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies with a site in Jinju.

How many clinical trials are recruiting in Jinju?

26 of the 58 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 31 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jinju), 58 studies
PhaseStudiesRecruitingShare
Phase 3331156.9%
Phase 27412.1%
Not applicable6410.3%
Observational538.6%
Phase 1426.9%
Phase 1/2111.7%
Phase 2/3111.7%
Phase 4101.7%

Most active sponsors

Lead sponsors with the most studies (Jinju)
Lead sponsorStudiesRecruiting
AstraZeneca144
BioNTech SE43
Novartis Pharmaceuticals41
Taiho Oncology, Inc.42
AbbVie32
Chonnam National University Hospital32
Eli Lilly and Company31
Samsung Medical Center31
Amgen20
BeOne Medicines21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.